DexCom, Inc. (NASDAQ:DXCM) EVP Sells $181,641.90 in Stock

DexCom, Inc. (NASDAQ:DXCM) EVP Jereme M. Sylvain sold 2,090 shares of the stock in a transaction dated Wednesday, January 29th. The shares were sold at an average price of $86.91, for a total transaction of $181,641.90. Following the completion of the transaction, the executive vice president now directly owns 83,526 shares in the company, valued at approximately $7,259,244.66. This represents a 2.44 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink.

DexCom Price Performance

Shares of DXCM stock traded up $1.19 on Thursday, hitting $87.62. 2,123,429 shares of the company’s stock were exchanged, compared to its average volume of 3,649,357. The company has a debt-to-equity ratio of 1.23, a current ratio of 2.46 and a quick ratio of 2.12. The stock has a market cap of $34.22 billion, a P/E ratio of 52.47, a price-to-earnings-growth ratio of 2.23 and a beta of 1.12. DexCom, Inc. has a 12 month low of $62.34 and a 12 month high of $142.00. The company has a 50 day moving average of $80.22 and a 200 day moving average of $76.59.

Institutional Investors Weigh In On DexCom

Several hedge funds and other institutional investors have recently made changes to their positions in the stock. Geode Capital Management LLC lifted its stake in DexCom by 2.2% in the 3rd quarter. Geode Capital Management LLC now owns 9,937,604 shares of the medical device company’s stock valued at $664,056,000 after purchasing an additional 214,136 shares during the last quarter. Jennison Associates LLC boosted its holdings in shares of DexCom by 10.3% during the 4th quarter. Jennison Associates LLC now owns 7,643,757 shares of the medical device company’s stock valued at $594,455,000 after acquiring an additional 710,858 shares in the last quarter. Groupama Asset Managment grew its position in DexCom by 1.1% during the 3rd quarter. Groupama Asset Managment now owns 2,851,556 shares of the medical device company’s stock worth $1,912,000 after acquiring an additional 31,358 shares during the last quarter. Westfield Capital Management Co. LP increased its holdings in DexCom by 44.6% in the 3rd quarter. Westfield Capital Management Co. LP now owns 2,842,057 shares of the medical device company’s stock worth $190,532,000 after purchasing an additional 876,739 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. raised its position in DexCom by 11.8% in the third quarter. Charles Schwab Investment Management Inc. now owns 2,734,155 shares of the medical device company’s stock valued at $183,298,000 after purchasing an additional 288,381 shares during the last quarter. 97.75% of the stock is owned by institutional investors.

Analyst Ratings Changes

DXCM has been the topic of a number of recent research reports. Raymond James lowered their target price on DexCom from $115.00 to $99.00 and set a “strong-buy” rating on the stock in a research note on Friday, October 25th. JPMorgan Chase & Co. lifted their target price on DexCom from $75.00 to $85.00 and gave the stock a “neutral” rating in a report on Friday, October 25th. Baird R W upgraded shares of DexCom from a “hold” rating to a “strong-buy” rating in a research note on Thursday, January 16th. Citigroup lifted their price objective on shares of DexCom from $85.00 to $91.00 and gave the stock a “buy” rating in a research note on Wednesday, December 11th. Finally, StockNews.com lowered shares of DexCom from a “buy” rating to a “hold” rating in a research report on Saturday, November 2nd. Five equities research analysts have rated the stock with a hold rating, twelve have given a buy rating and two have issued a strong buy rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $99.29.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.